EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY

Back

E-Poster

https://storage.unitedwebnetwork.com/files/1099/5ee890bc28f7a171cb83fd68c30b37cf.pdf

Abstract Title

First Name *

Vlado

Last Name *

Perkovic

Co-author 1

Dmitrij Kollins dmitrij.kollins@novartis.com Novartis Pharma AG Cardio-Renal-Metabolic GDD Basel

Co-author 2

Ronny Renfurm ronny.renfurm@novartis.com Novartis Pharma AG Cardio-Renal-Metabolic GDD Basel

Co-author 3

Olympia Papachristofi olympia.papachristofi@novartis.com Novartis Pharma AG GDD Biostatistics CRM Basel

Co-author 4

Severina Jacinto-Sanders severina.jacinto-sanders@novartis.com Novartis Pharma AG Medical Safety Cardio Metabolics Basel

Co-author 5

Tobias Merkel tobias.merkel@novartis.com Novartis Pharma AG Cardio-Renal-Metabolic GDD Basel

Co-author 6

Thomas Hach thomas.hach@novartis.com Novartis Pharma AG Cardio-Renal-Metabolic GDD Basel

Co-author 7

Dana V. Rizk drizk@uabmc.edu University of Alabama at Birmingham Division of Nephrology, Department of Medicine Birmingham

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15